Company intelligence
OWKIN
From token to patient impact
About OWKIN
Owkin is the vertical patient-driven layer that turns model companies frontier intelligence into expert- and experimentally validated biomedical outcomes, creating a new biology step to AGI.
Verified activity
Signals from OWKIN
16 published signals
Products & Services
OWKIN announced the launch of Initiative W, an independent, science-led effort focused on the safe development of AI at the intersection of biology and healthcare.
Reported by OWKIN
Presence & Recognition
OWKIN is heading to BioTechX Europe 2026 in Basel from October 6 to 8.
Reported by OWKIN
People
OWKIN hired Bryan Ly as a Research Intern to work within the Drug Discovery team on generative approaches, particularly flow matching models.
Reported by Bryan Ly
Research & Knowledge
OWKIN benchmarked K Pro against Claude on Anthropic’s BioMysteryBench test to quantify how K Pro adds value.
Reported by OWKIN
Research & Knowledge
OWKIN published HistoPLUS, a cell detection, segmentation, and classification model, as a peer-reviewed and open access paper in the Journal of Pathology Informatics.
Reported by OWKIN
Research & Knowledge
OWKIN demonstrated that the HistoPLUS model prediction for FGFR3 mutation status in bladder cancer is interpretable, driven by lower lymphocyte, plasmocyte, and fibroblast density, alongside higher cancer cell density and circularity.
Reported by OWKIN
Research & Knowledge
OWKIN demonstrated that the HistoPLUS model can find actionable biomarkers in bladder cancer using 290 TCGA-BLCA cases.
Reported by OWKIN
Research & Knowledge
OWKIN demonstrated that researchers can open a whole-slide image, inspect model-predicted tiles, and interrogate up to 50 tumor microenvironment features for biomarker analysis and patient subgrouping using HistoPLUS.
Reported by OWKIN
Research & Knowledge
OWKIN demonstrated that FGFR3 status determines eligibility for erdafitinib, with the model predicting FGFR3 mutation status in bladder cancer.
Reported by OWKIN
Partnerships
OWKIN announced a new strategic partnership with Boehringer Ingelheim to license K Pro, the AI Scientist, and multimodal patient data to support oncology and immunology pipelines.
Reported by OWKIN
Partnerships
OWKIN announced a new partnership with Boehringer Ingelheim to combine cutting-edge AI with multimodal data for drug discovery and development.
Reported by Teresa Pham
Products & Services
OWKIN launched the multimodal data catalog with BI.
Reported by John Wilbanks
Presence & Recognition
OWKIN CEO Thomas Clozel, MD will speak at the Nature Conferences on biology ASI in Paris, co-organized with PITOR - Paris Institute for Transplantation & Organ Regeneration, on September 8 at the Grand Amphithéâtre, Sorbonne University.
Reported by OWKIN
Research & Knowledge
OWKIN is hosting an upcoming webinar exploring how Owkin's AI scientist K Pro can analyze patient data and available literature to generate trial success probabilities.
Reported by OWKIN
Research & Knowledge
OWKIN evaluated Owkin's AI scientist K Pro's approach both retrospectively and prospectively with forecasts made before trial readouts.
Reported by OWKIN
Products & Services
OWKIN provides K Pro, an AI scientist with a Swiss Army knife harness for data access, agentic reasoning, skills, tools, code execution, and real-world validation.
Reported by OWKIN